103 related articles for article (PubMed ID: 27817860)
1. [Implementation of a nurse-driven educational program improves management of sorafenib's toxicities in hepatocellular carcinoma].
Brunot A; M'Sadek A; Le Roy F; Duval M; Le Sourd S; Ventroux E; Crouzet L; Guillygomarc'h A; Boucher E; Lelievre N; Laguerre B; Edeline J
Bull Cancer; 2016 Nov; 103(11):941-948. PubMed ID: 27817860
[TBL] [Abstract][Full Text] [Related]
2. Implementation of a Nurse-driven Educational Program Improves Management of Sorafenib's Toxicities in Hepatocellular Carcinoma.
Brunot A; Le Roy F; Le Sourd S; M'Sadek A; Duval M; Crouzet L; Guillygomarc'h A; Boucher E; Laguerre B; Edeline J
Cancer Nurs; 2018; 41(5):418-423. PubMed ID: 28731881
[TBL] [Abstract][Full Text] [Related]
3. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors.
Edeline J; Crouzet L; Le Sourd S; Larible C; Brunot A; Le Roy F; Cattenoz C; Latournerie M; Gédouin D; Guillygomarc'h A; Boucher E
Cancer Chemother Pharmacol; 2015 Jan; 75(1):215-9. PubMed ID: 25477009
[TBL] [Abstract][Full Text] [Related]
5. Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma.
Williet N; Clavel L; Bourmaud A; Verot C; Bouarioua N; Roblin X; Merle P; Phelip JM
Dig Liver Dis; 2017 Sep; 49(9):1043-1049. PubMed ID: 28712860
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
Turnes J; Díaz R; Hernandez-Guerra M; Gómez M; Castells L; Bustamante J; Espinosa MD; Fernández-Castroagudín J; Serrano T; Rendón P; Andrade R; Salgado M; Arenas J; Vergara M; Sala M; Polo BA; Granizo IM; Gonzálvez ML; Viudez A
Gastroenterol Hepatol; 2015 Apr; 38(4):263-73. PubMed ID: 25583146
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study.
Shiozawa K; Watanabe M; Ikehara T; Kogame M; Matsui T; Okano N; Kikuchi Y; Nagai H; Ishii K; Makino H; Igarashi Y; Sumino Y
Hepatogastroenterology; 2014 Jun; 61(132):885-91. PubMed ID: 26158136
[TBL] [Abstract][Full Text] [Related]
9. Tolerability of single-agent sorafenib in the treatment of elderly patients with hepatocellular carcinoma (HCC).
Francini E; Bianco V
Hepatology; 2014 Aug; 60(2):764-5. PubMed ID: 25187926
[No Abstract] [Full Text] [Related]
10. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E
J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964
[No Abstract] [Full Text] [Related]
11. Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
Brade AM; Ng S; Brierley J; Kim J; Dinniwell R; Ringash J; Wong RR; Cho C; Knox J; Dawson LA
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):580-7. PubMed ID: 26867886
[TBL] [Abstract][Full Text] [Related]
12. Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib.
Brandi G; De Lorenzo S; Di Girolamo S; Bellentani S; Saccoccio G; Biasco G
Tumori; 2015 Apr; 101(2):e46-8. PubMed ID: 25702656
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Ren Z; Zhu K; Kang H; Lu M; Qu Z; Lu L; Song T; Zhou W; Wang H; Yang W; Wang X; Yang Y; Shi L; Bai Y; Guo X; Ye SL
J Clin Oncol; 2015 Mar; 33(8):894-900. PubMed ID: 25667293
[TBL] [Abstract][Full Text] [Related]
14. Refining sorafenib therapy: lessons from clinical practice.
Bolondi L; Craxi A; Trevisani F; Daniele B; Di Costanzo GG; Fagiuoli S; Cammà C; Bruzzi P; Danesi R; Spandonaro F; Boni C; Santoro A; Colombo M
Future Oncol; 2015; 11(3):449-65. PubMed ID: 25360997
[TBL] [Abstract][Full Text] [Related]
15. Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study.
Daniele B; Croitoru A; Papandreou C; Bronowicki JP; Mathurin P; Serejo F; Stål P; Turnes J; Ratziu V; Bodoky G
Future Oncol; 2015 Sep; 11(18):2553-62. PubMed ID: 26158398
[TBL] [Abstract][Full Text] [Related]
16. Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib.
Shin SY; Lee YJ
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):837-46. PubMed ID: 24075093
[TBL] [Abstract][Full Text] [Related]
17. Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma.
Garuti F; Camelli V; Spinardi L; Bucci L; Trevisani F
Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27079903
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
[TBL] [Abstract][Full Text] [Related]
19. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.
Raoul JL; Kudo M; Finn RS; Edeline J; Reig M; Galle PR
Cancer Treat Rev; 2018 Jul; 68():16-24. PubMed ID: 29783126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]